With high levels of tumor-infiltrating lymphocytes (TILs) and PD-L1 expression, TNBC exhibits stronger immunogenicity than other subtypes of breast cancer and may be more likely to benefit from immunotherapy [10,11,12,13,14,15]. This evidence concerns the gene CD274 and breast cancer.